Q-omics provides the consensus-scored MSC profile across patient tissues and cancer cell-line models. MSC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MSC is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MSC RNA expression shows 16,306 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where MSC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSC survival associations across molecular data types. MSC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSC RNA expression–survival associations across cancer types. High MSC expression shows unfavorable associations in KIRC, MESO, SKCM and LIHC, but favorable associations in UVM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MSC RNA expression.
This table summarizes MSC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MSC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSC shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, STAD, KIRP and COAD. The KIRC box plot shows higher MSC RNA expression in tumor versus normal tissue (log2 FC = +3.243, t-test p < 0.001).
This table shows molecular features associated with MSC in patient tissues and cancer cell lines. In patient samples, MSC shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MSC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
